Based on the ODYSSEY Outcomes Trial, specifically the low LDL-C levels achieved without adverse consequences, what target level of LDL-C do you recommend in medically managed patients with moderate-to-high risk features of ASCVD?

http://cmr.2.2.broadcastmed.net/videos/from-a-medical-cardiologist-s-perspective-which-patient-subgroups-in-your-practice-do-you-feel-represent-ideal-candidates-for-deployment-of-pcsk9-inhibitors-to-lower-ldl-c-levels-based-on-the-results-of-the-odyssey-outcomes-and-fourier-t/flushcache/1/showdraft/1